Inactive Instrument

PCI Biotech Holding ASA

PCIB

NO0010405640

Biotechnology & Medical Research

Received application for delisting

Published on 03/17/2026 at 03:12 pm EDT

Acquiremedia

PCI BIOTECH HOLDING ASA

-.--%

Euronext Oslo Børs has received an application from PCI Biotech Holding ASA for
the delisting of the company's shares from Euronext Oslo Børs.

Click here for more information

Latest news about PCI Biotech Holding ASA

03-24	Euronext Oslo Børs Sets Delisting Date for Norway's PCI Biotech	MT
03-24	Euronext Oslo Børs to delist PCI Biotech Holding shares	RE
03-17	PCI Biotech Applies to Delist From Euronext Oslo Børs	MT
03-17	Euronext Oslo Børs gets application from PCI Biotech Holding for delisting	RE
02-23	Pci Biotech Holding board proposes dissolution, delisting	RE
01-30	Oslo Bors: PCI Biotech Holding is placed in recovery box	RE
01-29	PCI Biotech says co initiates process to evaluate opportunity for structured wind-up process	RE
01-08	PCI Biotech Holding ASA Announces Discontinuation of R&D Operations and Continues Evaluation of Future Options	CI
01-08	PCI Biotech to Shut Down Research, Development Operations; Liquidity Position 'Critical'	MT
01-08	Pci Biotech announces discontinuation of research and development operations	RE
25-10-23	PCI Biotech Warns of 'Critical' Liquidity Position Amid Ongoing Technology Review	MT
25-10-23	Pci biotech updates on evaluation of operations	RE
25-09-25	Pci Biotech reduces personnel, extends wind-down of ops	RE
25-08-29	Pci Biotech H1 comprehensive loss NOK 11.5 mln	RE
25-08-28	PCI Biotech Holding ASA Reports Earnings Results for the Half Year Ended June 30, 2025	CI

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotechâ€™s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

Employees

Sector

Biotechnology & Medical Research

More about the company